Keymed Biosciences Announces Approval of IND for CM518D1 by the National Medical Products Administration of China for the Treatment of Solid Tumors
CHENGDU, China, April 25, 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" or the "Company") today announced CM518D1, a CDH17-targeted antibody-drug conjugate (ADC) developed by Keymed, received Investigational New Drug (IND) approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA), and is currently undergoing Phase I/II clinical trials in China for the treatment of...
Announcement of Paper Publication: EditForce Demonstrates Efficacy of Treatment for Myotonic Dystrophy Type 1 Using PPR Platform Technology
FUKUOKA, Japan, April 25, 2025 /PRNewswire/ -- EditForce, Inc. (Headquarters: Fukuoka, Japan) is pleased to announce that a research paper on the results of a joint study with the research group led by Professor Masayuki Nakamori of the Department of Neurology of the Yamaguchi University Graduate School of Medicine, and Professor Hideki Mochizuki of the Department of Neurology...
Sanofi and Sobi extend their partnership with the World Federation of Hemophilia Humanitarian Aid Program
Up to five-year contract extension to support the WFH Humanitarian Aid Program with medicine donations and financial assistance MONTREAL, April 25, 2025 /PRNewswire/ -- The World Federation of Hemophilia (WFH) and WFH USA, together with Sanofi, through its philanthropic organization Foundation S, and Sobi, announce the signing of a contract providing...
Keymed Biosciences Announces Approval of IND for CM518D1 by the National Medical Products Administration of China for the Treatment of Gastrointestinal Cancers
CHENGDU, China, April 25, 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" or the "Company") recently announced CM518D1, a CDH17-targeted antibody-drug conjugate (ADC) developed by Keymed, received Investigational New Drug (IND) approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA), and is currently undergoing Phase I/II clinical trials in China for the treatment of...
Akeso Announces FDA Approval for Penpulimab-kcqx in Two BLA Indications for Comprehensive Treatment of Advanced Nasopharyngeal Carcinoma
HONG KONG, April 25, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that the U.S. Food and Drug Administration (FDA) has approved its differentiated PD-1 monoclonal antibody, penpulimab-kcqx, in combination with cisplatin or carboplatin and gemcitabine for the first-line treatment of adult recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (NPC). FDA also approved...
A Visionary Breakthrough: VISTA Eye Specialist and EssilorLuxottica Join Forces to Combat Childhood Myopia in Malaysia
PETALING JAYA, Malaysia, April 25, 2025 /PRNewswire/ -- In a landmark move to safeguard the vision of Malaysia's future generation, VISTA Eye Specialist ('VISTA'), the nation's trusted eye care brand, announced a strategic collaboration Memorandum of Understanding (MoU) with EssilorLuxottica, the global leader in Medtech for vision care. VISTA Eye Specialist signs MoU with...
Medit and Graphy Announce Strategic Partnership to Advance Digital Orthodontics
SEOUL, South Korea, April 25, 2025 /PRNewswire/ -- Medit, a global leader in digital dentistry solutions, and Graphy, a leading innovator in 3D printing dental materials, have officially announced a strategic partnership to accelerate advancements in the digital orthodontics market. Medit and Graphy Announce Strategic Partnership to Advance Digital Orthodontics The partnership brings...
VivaVision Announces Positive Topline Results from Phase 2 Trial of VVN461 for Non-Infectious Anterior Uveitis
VVN461, a dual JAK1/TYK2 inhibitor as a non-steroidal anti-inflammatory agent, has met primary endpoints, demonstrating non-inferior efficacy compared to the standard therapy, prednisolone acetate (PA) in treating NIAU Clinically meaningful reductions in inflammation compared to baseline observed as early as Day 3 Strong safety profile with no substantial treatment-related adverse events reported WENZHOU, China, April 25, 2025...
Primo’s Taoyuan Facility Achieves PIC/S GMP Certification, Paving the Way for Global Expansion in Nuclear Medicine.
TAIPEI, April 24, 2025 /PRNewswire/ -- Primo Biotechnology Co., Ltd. ("Primo") proudly announces that its Taoyuan pharmaceutical facility has successfully passed inspection by Taiwan Food and Drug Administration (TFDA) and has been award dual certification for PIC/S GMP and GDP. This achievement demonstrates Primo's dedication to meeting international quality standards for nuclear medicine production and sets the stage...
Abu Dhabi Pioneers Collaborative Approach to Responsible AI in Healthcare at Health Leaders Roundtable
Held during Abu Dhabi Global Health Week, the roundtable united global health leaders to shape a Declaration on AI governance principles for healthcare This collaborative dialogue explored key challenges and opportunities in unlocking AI's potential, and the optimal governance principles required to develop an agile framework for effectively integrating AI in...
